References
- WHO. Fact sheet N°380: human papillomavirus (HPV) and cervical cancer. Available from: www.who.int/mediacentre/factsheets/fs380/en/ [Last accessed November 2014]
- Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007;356(19):1928-43
- De Vincenzo R, Conte C, Ricci C, et al. Long-term efficacy and safety of human papillomavirus vaccination. Int J Womens Health 2014;6:999-1010
- Holman DM, Benard V, Roland KB, et al. Barriers to human papillomavirus vaccination among US adolescents, a systematic review of the literature. JAMA Pediatr 2014;168(1):76-82
- Dorleans F, Giambi C, Dematte L, et al. On behalf of the VENICE 2 project gatekeepers group. The current state of introduction of human papillomavirus vaccination into national immunisation schedules in Europe: first results of the VENICE2 2010 survey. Euro Surveill 2010.15(47):19730. Available from: www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19730
- Garattini L, van de Vooren K, Curto A. Pricing human papillomavirus vaccines: lessons from Italy. Pharmacoeconomics 2012;30:213-17
- Garattini L, Van de Vooren K. Are high prices a barrier to human papillomavirus vaccination in the United States? Not in Italy. JAMA Pediatr 2014;168(6):584
- Available from: www.arca.regione.lombardia.it/shared/ccurl/283/808/ARCA_2014_03_V7_aggiudicazione.pdf [Last accessed 22 November 2014]
- Garattini L, Van de Vooren K, Freemantle N. Tendering and value-based pricing: lessons from Italy on human papilloma virus vaccines. J R Soc Med 2014;107(1):4-5
- Zimet GD, Rosenthal SL. HPV vaccine and males: issues and challenges. Gynecol Oncol 2010;117:S26-31
- Garattini L, Van de Vooren K. HPV vaccination for boys? Talking economic sense. J Sex Med 2012;9(8):2195-6
- Contract for the supply of human papillomavirus vaccine in UK. 2011. Available from: www.contractsfinder.businesslink.gov.uk/Common/View%20Notice.aspx?site=1000&lang=en¬iceid=184264&fs=true [Last accessed 14 July 2011]
- Jit M, Brisson M, Laprise JF, et al. Comparison of two dose and three dose human papillomavirus vaccine schedules: cost effectiveness analysis based on transmission model. BMJ 2014;350:g7584
- FDA News Release. FDA approves Gardasil 9 for prevention of certain cancers caused by five add. Available from: www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm426485.htm [Last accessed 10 December 2014]
- Koleva D, De Compadri P, Padula A, et al. Economic evaluation of human papilloma virus vaccination in the European Union: a critical review. Intern Emerg Med 2011;6:163-74
- Newal AT, Beutels P, Wood JG, et al. Cost effectiveness analyses of human papillomavirus vaccination. Lancet Infect Dis 2007;7:289-96
- Puig-Junoy J, Lopez-Valcarcel BG. Economic evaluations of massive HPV vaccination: within study and between study variations in incremental cost per QALY gained. Prev Med 2009;48:444-8
- Laprise JF, Drolet M, Boily MC, et al. Comparing the cost-effectiveness of two- and three-dose schedules of human papillomavirus vaccination: a transmission-dynamic modelling study. Vaccine 2014;32(44):5845-53
- Drolet M, Laprise JF, Boily MC, et al. Potential cost-effectiveness of the nonavalent HPV vaccine. Int J Cancer 2014;134(9):2264-8
- Safaeian M, Porras C, Pan Y, et al. Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial. CVT Group. Cancer Prev Res (Phila) 2013;6(11):1242-50
- Schiller JT, Lowy DR. Raising expectations for subunit vaccine. J Infect Dis 2014. [Epub ahead of print]